After a paper published last week in the journal Lancet showed coronavirus patients who took hydroxychloroquine faced a higher risk of death, the World Health Organization has announced a "temporary pause" on its global clinical trial of the anti-malarial drug.
Though acknowledging there have been no safety problems with hydroxychloroquine emerging from their study to this point, WHO officials confirmed that until a comprehensive review of all available data is complete, the trial of experimental treatments for COVID-19 will move forward with just an HIV combination therapy and the drug remdesivir.
"We're just acting on an abundance of caution based on the recent results of all the studies to ensure that we can continue safely with that arm of the trial," an official said.
Hydroxychloroquine is currently prescribed to prevent malaria, as well as treat conditions like lupus and rheumatoid arthritis.
? President Trump said last week that he was taking hydroxychloroquine as a preventative.